Komori
Share Issuance and Disposal4582SymBio Pharmaceuticals LimitedPharmaceuticals

Notice of Completion of Payment for the 2nd Unsecured Straight Bond (Private Placement)

Payment of the total amount of ¥100 million for the 2nd unsecured straight bonds (private placement), approved on 17 August 2026, has been completed.

Worth reading
52Recurring
Scored from 3 of 5 sections
Direction
Neutral
Direction inferred from the company’s description.
Scale
100000000
¥
Wording
Definitive
How definitive the wording is.

Details of issuance or disposal

Issuance of unsecured straight bonds (private placement)

Intended allottee
EVO FUND (subscriber for the entire amount)
Amount of funds to be raised

Total payment amount: ¥100,000,000; estimated net proceeds: Not disclosed

Payment date
3 September 2026
Most recent equity financing
Issuance of the 70th and 71st stock acquisition rights with provisions for adjustment of the exercise price, approved on 17 August 2026 (detailed amounts are not stated in this document)
Details of issuance or disposal
ItemDetails
Type of issuance or disposalIssuance of unsecured straight bonds (private placement)
Issue price and disposal price¥100 per ¥100 of face value
Amount of funds to be raisedTotal payment amount: ¥100,000,000; estimated net proceeds: Not disclosed
Payment date3 September 2026
Intended allotteeEVO FUND (subscriber for the entire amount)
Most recent equity financingIssuance of the 70th and 71st stock acquisition rights with provisions for adjustment of the exercise price, approved on 17 August 2026 (detailed amounts are not stated in this document)
Items this document does not state (22)
Number of shares to be issued or disposed ofTotal issue valueEstimated issuance expensesSpecific use of fundsIntended allottee's holding policyDilution RateTotal number of issued sharesBasis for determining the amount to be paidExercise priceExercise periodNumber of Stock Acquisition RightsTransfer restriction periodConditions for lifting transfer restrictionsReason for acquisition without considerationCategories and Number of Persons CoveredTotal Stock-Based CompensationUnderwriter / lead underwriterOverallotmentStock Split RatioProcedures under the Corporate Code of ConductMajor shareholders after the offeringImpact on Business Performance

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

The Company confirmed completion of payment for these bonds based on the resolution of the Board of Directors dated 17 August 2026.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice of Completion of Payment for the 2nd Unsecured Straight Bond (Private Placement) | SymBio Pharmaceuticals Limited (4582) timely disclosure | Komori